HIT Consultant – Read More
What You Should Know:
– myTomorrows, a health technology company that connects patients with all possible pre-approval treatments, today announced the close of a $29 million financing with Avego. Avego’s growth equity investment will fuel the global expansion of myTomorrows’ integrated pharma solutions to make emerging treatments more equitable and accessible for patients globally.
– With more than 300 million patients worldwide facing conditions without approved treatment options, and over 10,000 therapies currently in development or awaiting approval – myTomorrows is addressing one of healthcare’s most urgent challenges: bridging the gap between scientific advancement and patient access to pre-approval treatments, which include clinical trials and expanded access programs (EAPs).
myTomorrows Expands Global AI Platform to Accelerate Patient Access to Pre-Approval Treatments
myTomorrows is redefining how patients and physicians access investigational therapies by bridging the gap between clinical development and real-world care. The global HealthTech company operates a unified, multi-stakeholder platform that connects patients, physicians, trial sites, and BioPharma partners—simplifying access to pre-approval treatments through the power of AI and expert human navigation. By bringing transparency, coordination, and insight to the treatment discovery process, myTomorrows is accelerating global access to innovative therapies while advancing data-driven drug development.
The latest investment will fuel the company’s international expansion and further enhance its AI-driven global platform—deepening integration with BioPharma partners to shorten clinical development timelines, enrich real-world evidence generation, and strengthen regulatory insight. “This investment marks a pivotal step in our journey to give every patient, no matter where they live, a fair shot at tomorrow’s therapies,” said Michel van Harten, CEO of myTomorrows. “Avego’s deep life sciences expertise, especially in BioPharma, will be instrumental as we scale our platform and broaden our global impact.”
Today, myTomorrows operates the world’s most comprehensive AI-powered platform for pre-approval treatments, having already supported more than 16,900 patients across 133 countries. The platform empowers patients and clinicians through expert guidance, personalized treatment matching, and seamless access to both clinical trials and expanded access programs. For BioPharma partners, it offers end-to-end services in trial recruitment, expanded access management, and real-world data capture, while trial sites benefit from unified referral systems with real-time tracking and enhanced visibility.
By connecting every stakeholder in the treatment ecosystem, myTomorrows is laying the foundation for a new era of global healthcare access—one defined by AI-enabled precision, adaptive regulation, and empowered patients. Embedded across health systems worldwide, its platform provides unbiased, actionable pathways to emerging therapies, ensuring that medical breakthroughs reach those who need them most—exactly when it matters.
